PHASER Expands Pharmacogenomics Across the VA
Healthcare is changing, and genetics is helping lead the way. Pharmacogenomics, or PGx, looks at how a person’s genes affect the way they…
-
-
The FDA Finally Acts on DPYD Testing
On October 30, 2025, the U.S. Food and Drug Administration quietly made a major update to the label for capecitabine (Xeloda®). It now…
-
Can AI Be Trusted to Guide Pharmacogenomics Decisions? Sherpa Rx
Artificial intelligence is beginning to find its footing in one of medicine’s most nuanced frontiers: pharmacogenomics — the science of matching medications to…
-
Why Do Pharmacogenomic Guidelines Vary So Widely Between Countries?
Pharmacogenomics—the study of how genes affect a person’s response to drugs—is transforming modern medicine. By tailoring drug treatments based on genetic profiles, it…
-
Efavirenz and CYP2B6: What All HIV Patients Need to Know
Efavirenz has helped millions of people living with HIV achieve viral suppression, especially in countries where access to newer antiretroviral drugs remains limited….
-
American Pharmacogenomics Association Names Lydia Kariuki as Managing Editor of Business-Focused Industry Blog
FOR IMMEDIATE RELEASE Seasoned Business Writer with Two-Decade History Brings Deep Industry Market Expertise to Lead APGxA’s Digital Content Strategy SAN LUIS OBISPO,…
-
Lessons from COVID-19: Pharmacogenomics in Preparing for Future Pandemics
The COVID-19 pandemic has posed unprecedented challenges, prompting a critical inquiry: Might our genetic makeup hold the key to more effective treatments in…
-
The Challenges and Future of Cancer Pharmacogenetics
Explore the challenges and future of cancer pharmacogenetics as we delve into personalized medicine’s role in oncology treatment.
-
Pharmacogenomics for Drug Dosing in Children
Explore how pharmacogenomics for drug dosing in children is revolutionizing personalized medicine and ensuring safer, effective treatments.
End of content
End of content